Clinical Trial Update: Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating gemcitabine plus ivonescimab for advanced non-small cell lung cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING